Mirion Technologies Q2 FY26 earnings call MIR

Mirion highlighted significant momentum in the nuclear power sector, particularly in North America. Regulatory improvements from the NRC and the Department of Energy's $17.5 billion loan program are opening financing and regulatory gateways. The DOE's Reactor Pilot Program achieved criticality across four advanced reactor designs, outperforming its target. New power deals, such as Constellation and Walmart's agreement, and advancements in nuclear plans in New York State and Canada, further underscore the growing demand. Globally, the World Nuclear Association forecasts a tripling of nuclear capacity by 2050 to nearly 1.5 terawatts, a 45% increase from a decade ago, indicating sustained demand for Mirion's solutions.

The company identifies three waves driving order growth from the installed nuclear base. The first is 'catch-up^📎 capital spending,' addressing deferred maintenance and replacement parts due to past capital rationing, fueled by plant restarts and demand for commercial-grade dedication and spare parts from the PeAks platform. The second wave involves 'life extensions and extended power upgrades,' as operators commit to 10-20 year extensions, triggering upgrades to instrumentation and controls. The third, emerging wave is 'digital transformation,' driven by an aging workforce and the need for digital platforms to capture expertise, optimize outages, and improve thermal efficiency.

Mirion is strategically investing in AI across three pillars to gain an early adopter advantage. The first pillar focuses on accelerating product development by embedding AI into software development cycles, improving data analytics, real-time feedback loops, and testing/compliance workflows. The second pillar aims for organization-wide efficiencies, using AI for automating back-office processes and test plan development. The third, and most exciting, pillar is developing AI-powered solutions, such as the new Plan AI dosimetry platform for faster, higher-quality patient-specific plans, and Daily QA 4 Pro, which consolidates dosimetry and imaging checks for improved efficiency in cancer treatment centers.

Management emphasized continuous scrutiny of its backlog, noting that debooking events are exceedingly rare and typically tied to broader issues. The recent $18 million cancellation of a Chinese new build order, originally booked in 2019, was attributed to geopolitical tensions and stalled project progress. Despite this, the company asserts no impact on its 2026 guidance or long-range plans, maintaining confidence in its overall backlog quality. Mirion continues to have a meaningful position in 50 out of 60 operating Chinese reactors, with a robust spare parts market averaging $8 million annually, and ongoing export opportunities for new builds and advanced reactor applications.

Mirion maintains a strong M&A pipeline, viewing it as a critical component of its strategy, having completed approximately 20 deals over the last decade. The company expects to remain active in this area, targeting highly complementary assets. In terms of capital allocation, without further M&A, Mirion projects ending the year at approximately 2.5x leverage, indicating a net reduction in leverage. The company's first strategic priority for capital allocation remains M&A, with a focus on smaller-sized deals.

The Medical segment experienced a 1% organic revenue decline in Q2, below expectations, primarily due to nuclear medicine and dosimetry. RTQA revenue continued to grow, driven by OEM sector performance and software. Nuclear medicine saw delayed hardware demand, though its software business generated strong double-digit order growth in H1, and factory improvements have reduced lead times. Dosimetry faced negative organic growth due to tough hardware comparables. Despite these mixed results, the company maintained its full-year Medical segment guidance, with RTQA's raised outlook offsetting the lowered expectations for nuclear medicine and dosimetry.